The bull case for Pfizer After losing patent protection of Lipitor, the company's megablockbuster LDL-lowering medicine, Pfizer's top-line has been heading in wrong direction. However, the company looks finally poised for growth again due to a handful of newly launched drugs that look poised for growth.